Scholarlink

Background <p>Breast cancer, particularly the human epidermal growth factor receptor 2 positive subtype, presents a significant global health challenge due to its high prevalence and mortality rates. This study delves into the molecular intricacies of HER-2 positive breast cancer, with an emphasis on the role of the HER-2 oncoprotein and its associated signaling pathways in cell growth, differentiation, and survival. In our pursuit of overcoming the limitations of one of the leading therapeutic options, Lapatinib, such as its inhibition of hERG, we embarked on a comprehensive research journey.</p> Result <p>This study involved dual-stage molecular docking, initially with a library of PubChem-curated compounds, revealing Compound 90196902 as the best of the set. This was followed by the docking of DataWarrior-generated structural analogs of Compound 90196902, using various docking protocols such as standard precision, extra precision, and induced fit docking. Through this rigorous screening protocol, three promising drug candidates (Compound_56, Compound_81, and Compound_339) were identified, showing excellent interaction with the target. Additionally, binding free energy calculations, ADME and toxicity profiling, and molecular dynamics simulations presented these compounds as lead-like.</p> Conclusion <p>Compound_56 showed the most promising pharmacodynamic and pharmacokinetic properties, coupled with substantial structural stability. While immensely promising, further optimization and pre-clinical investigation are imperative to validate this compound as a viable alternative to existing therapies for HER-2 positive breast cancer.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Leveraging computational approaches in identifying novel HER-2 + breast cancer potential therapeutics: integrating virtual screening and molecular dynamics simulation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年1月6日

查看全文
  • Olawale Quadri Bolaji,
  • Temitope Isaac Adelusi,
  • Taiwo Ooreoluwa Ojo,
  • Ibrahim Damilare Boyenle,
  • Abdul-Quddus Kehinde Oyedele,
  • Taiwo Temitope Ogunjobi,
  • Adegboye Oyewole Oyaronbi,
  • Sukurat Oluwatoyin Ayoola,
  • Abdeen Tunde Ogunlana

摘要

Background

Breast cancer, particularly the human epidermal growth factor receptor 2 positive subtype, presents a significant global health challenge due to its high prevalence and mortality rates. This study delves into the molecular intricacies of HER-2 positive breast cancer, with an emphasis on the role of the HER-2 oncoprotein and its associated signaling pathways in cell growth, differentiation, and survival. In our pursuit of overcoming the limitations of one of the leading therapeutic options, Lapatinib, such as its inhibition of hERG, we embarked on a comprehensive research journey.

Result

This study involved dual-stage molecular docking, initially with a library of PubChem-curated compounds, revealing Compound 90196902 as the best of the set. This was followed by the docking of DataWarrior-generated structural analogs of Compound 90196902, using various docking protocols such as standard precision, extra precision, and induced fit docking. Through this rigorous screening protocol, three promising drug candidates (Compound_56, Compound_81, and Compound_339) were identified, showing excellent interaction with the target. Additionally, binding free energy calculations, ADME and toxicity profiling, and molecular dynamics simulations presented these compounds as lead-like.

Conclusion

Compound_56 showed the most promising pharmacodynamic and pharmacokinetic properties, coupled with substantial structural stability. While immensely promising, further optimization and pre-clinical investigation are imperative to validate this compound as a viable alternative to existing therapies for HER-2 positive breast cancer.

Graphical abstract